drugset / Trial / NCT04149275
Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic Carcinosarcoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety of Cabozantinib in combination with Nivolumab and Ipilimumab and see what affects that this combination treatment has on those with recurrent carcinosarcomas.
Timeline
- Start
- 2021-02
- Primary completion
- 2021-02
- Completion
- 2021-02
Outcome
Outcome not reported
Stopped (Business): “Funding withdrawn by sponsor”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabozantinib | Small molecule | — | Oral |
| Subject | Ipilimumab | Monoclonal antibody | — | Intravenous |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |